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ABSTRACT
The Sherlock Mycobacteria Identiﬁcation HPLC
system correctly identiﬁed to the species level 61
(67.8%) of 90 isolates growing on solid media,
and 73 (45.3%) of 161 isolates directly from
positive VersaTREK Myco bottles. When these
data were re-analysed with a revised database,
correct identiﬁcations increased to 91.1% and
83.2%, respectively. All Mycobacterium tuberculosis
isolates were identiﬁed correctly, regardless of the
inoculum source or database used. The use of the
revised database with isolates obtained directly
from positive VersaTREK Myco bottles allows the
identiﬁcation of most isolates within clinically
relevant time-frames.
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The use of continuously monitored liquid-based
culture systems for mycobacteria has resulted in
decreased times to detection for positive cultures.
In addition, various species of clinically relevant,
non-tuberculous mycobacteria are now isolated
routinely with increasing frequency [1–3]. Several
investigators have used nucleic acid probes to
identify mycobacteria directly from positive cul-
ture bottles or tubes, but these probe-based
identiﬁcations are restricted to a few species [4–
6]. High-performance liquid chromatography
(HPLC) is an alternative identiﬁcation method,
but is generally performed from solid media and
requires manual inspection of mycolic acid chro-
matographic proﬁles, as well as extensive exper-
tise. The purpose of the present study was to
investigate the use of a commercially available
HPLC system with pattern recognition software
for the identiﬁcation of mycobacteria obtained
from solid media and directly from positive broth
culture bottles.
Clinical specimens received for mycobacterial
culture were processed by standard laboratory
protocols and inoculated on to Middlebrook 7H11
agar plates (BBL, Sparks, MD, USA) and into
VersaTREK Myco bottles containing growth sup-
plement and PVNA (polymyxin B, vancomycin,
nalidixic acid, amphotoricin B) antibiotic mixture
(TREK Diagnostic Systems, Cleveland, OH, USA).
These bottles were incubated in the ESP Culture
System II (TREK Diagnostic Systems) and the
VersaTREK system when available. Bottles were
monitored continuously for growth and an
aliquot was removed for identiﬁcation when a
positive culture was detected. All clinical isolates
were identiﬁed initially using nucleic acid probes
as described previously [5]. If the isolates could
not be speciated using probes, they were identi-
ﬁed by biochemical testing [7]. New clinical
isolates were tested by HPLC in real-time as the
cultures became positive. In total, 90 isolates were
tested from solid media (45 from concurrent
positive cultures and 45 from subcultured frozen
stock cultures), and 161 isolates were tested
directly from positive VersaTREK Myco bottles
(120 from concurrent positive cultures and 41
seeded from subcultured stock cultures).
For theHPLCassay, a sterile applicator stickwas
used to pick up a barely visible amount of growth
from solid media for processing, or the pellet from
3 mL of broth, centrifuged at 3000 g for 30 min,
was used from a positive VersaTREK Myco bottle.
Saponiﬁcation, extraction and derivatisation
were performed according to the manufacturer’s
instructions (MIDI Inc., Newark, DE, USA).
An Agilent 1100 Series HPLC system (Agilent
Technologies, Wilmington, DE, USA) with a C18
reverse phase column was used to analyse the
mycolic acid content of the samples. A calibration
standard (in duplicate) and the specimen samples
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were injected into the column and eluted with a
gradient of methanol ⁄ isopropanol. Each specimen
required c. 13 min for elution and data analysis.
The entire procedurewas completedwithin 8 h. At
the beginning of each run, the calibration standard
provided mycolic acid reference retention times,
which were used to calculate equivalent carbon
length values. Sample chromatographic proﬁles
were then compared with existing proﬁles con-
tained in the database. Reports include an identi-
ﬁcation for each isolate, along with a similarity
index (SI). An acceptable identiﬁcation required an
SI of ‡ 0.5, with a minimum of 0.2 SI separation
from the next closest species identiﬁcation.
All samples were analysed with the current US
Food and Drug Administration-approved library
(Library 1.02) and the updated database (Library
1.03). Both results were compared with identiﬁ-
cations made with nucleic acid probes and ⁄ or
conventional biochemical tests. Five isolates, three
Mycobacterium scrofulaceum, one Mycobacterium
interjectum and one Mycobacterium xenopi, were
re-tested by the New York City Department of
Health with a different HPLC method because of
apparent discrepancies between the MIDI HPLC
and conventional identiﬁcation results.
The results obtained with isolates grown on
7H 11 medium are shown in Table 1. Of the 90
isolates, encompassing 18 species, 61 (67.7%)
were identiﬁed correctly by HPLC, which is
similar to the rate of correct results (75%) repor-
ted previously with use of this system [8].
Another three isolates were identiﬁed correctly,
but there was < 0.2 SI difference between the
ﬁrst and second identiﬁcations. Four additional
isolates were identiﬁed correctly to the species
complex. It is of note that M. scrofulaceum (con-
tained within the Mycobacterium avium–Mycobac-
terium intracellulare–M. scrofulaceum complex) was
not contained in Library 1.02. However, only two
of the 16 M. scrofulaceum isolates were identiﬁed
accurately as part of this complex. The Library
1.02 database identiﬁed correctly only 73 (45.3%)
of the isolates obtained directly from positive
Myco bottles (Table 2). Another seven isolates
were identiﬁed correctly, but with < 0.2 SI separa-
tion between the ﬁrst two choices. Another 58
isolates were identiﬁed correctly to the species
complex.
With the Library 1.03 database, the overall
agreement increased to 91.1% for isolates from
solid media (Table 1), and to 83.2% for isolates
from the VersaTREK Myco bottles (Table 2).
Among isolates from solid media, all of the
M. avium complex isolates were identiﬁed cor-
rectly, as were 15 of the 16 isolates of M. scrofu-
laceum. Among isolates obtained from Myco
bottles, 62 of 81 M. avium complex isolates were
identiﬁed correctly, with an additional nine iso-
lates with < 0.2 SI between the top two choices.
Fifteen of the 18 M. scrofulaceum isolates were
also identiﬁed. In all cases, isolates of Mycobacte-
Table 1. Identiﬁcation of mycobac-
terial isolates grown on solid media
with the MIDI HPLC system
Organism n Stock culture Real-time
Library 1.02
Library 1.03
No. correctNo. correct
No. correct
< 0.2 SI
Correct
to complex
M. abscessusa 9 1 8 9 9
M. asiaticum 1 1 0 1 1
M. avium complex 25 4 21 20 2 2 25
M. bovis BCG 1 0 1 1 1
M. celatum 3 3 0 3 3
M. chelonaeb 3 0 3 3 3
M. fortuitum 1 1 0 1 1
M. gordonae 2 0 2 2 2
M. haemophilum 8 7 1 7 1 7
M. interjectum 2 1 1 0 1
M. kansasii 2 2 0 2 2
M. malmoense 1 1 0 1 1
M. mucogenicum 2 2 0 0 0
M. scrofulaceum 16 16 0 0c 2 15
M. simiae 2 2 0 0 0
M. terrae complex 2 0 2 2 2
M. tuberculosis 4 0 4 4 4
M. xenopi 6 4 2 5 5
Totals 90 45 45 61 (67.8%) 3 4 82 (91.1%)
aIdentiﬁed as M. abscessus ⁄ chelonae.
bIdentiﬁed as M. chelonae ⁄ abscessus.
cM. avium–M. intracellulare–M. scofulaceum complex only in Library 1.02.
SI, similarity index.
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rium tuberculosis were identiﬁed accurately;
however, the system cannot differentiate among
the species in the M. tuberculosis group, with the
exception of Mycobacterium bovis BCG.
The development of automated pattern
recognition software that analyses HPLC peak
retention times and characteristics allows this
methodology to be used in routine clinical micro-
biology laboratories. Library 1.02 was developed
from isolates grown on 7H10 agar. However, this
proved to be inadequate when used with isolates
obtained from liquid media. The major improve-
ments seen in the revised database were the
inclusion of M. scrofulaceum in the M. avium–
M. intracellulare–M. scrofulaceum complex and the
reﬁnement in the identiﬁcation of M. avium iso-
lates. The other non-tuberculous mycobacterial
species were identiﬁed correctly in 42 of 49 cases
from solid media, and in 57 of 62 cases from the
Myco bottles. The Mycobacterium simiae isolates
were identiﬁed as Mycobacterium lentiﬂavum ⁄My-
cobacterium triplex, which have been reported to
have similar mycolic acid proﬁles [9]. The two
isolates of Mycobacterium mucogenicum in the
present study were identiﬁed as Mycobacterium
fortuitum ⁄Mycobacterium peregrinum.
The MIDI HPLC system, combined with Lib-
rary 1.03, is feasible for use in the routine
laboratory to identify mycobacterial isolates in
real-time. The instrument costs 55 000 Euro; each
run requires two standards and two control
isolates at a cost of c. 11 Euro, each sample costs
c. 4 Euro, and one calibrator must be re-run after
every ten samples. The system obviates the need
for using more expensive nucleic acid probes and
most routine biochemicals. The MIDI HPLC
system with the updated Library is capable of
identifying most clinical isolates within clinically
relevant time-frames.
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ABSTRACT
A novel DNA strip assay, GenoType Mycobacter-
ium AS, was evaluated for its ability to identify
219 mycobacterial isolates in combination with
the GenoType Mycobacterium CM assay. The
results were compared with those obtained by
conventional 16S rDNA sequencing. The Geno-
type test correlated well (96%) with sequencing.
However, with the CM kit alone, it was possible
to identify most (88%) of the isolates found in
clinical specimens, and the AS kit provided very
little additional information.
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Non-tuberculous mycobacteria are isolated
increasingly from patient specimens in countries
where the incidence of tuberculosis is low [1], and
there is a need for rapid methods for their
identiﬁcation. Two DNA line probe assays,
INNO-LiPA Mycobacteria (Innogenetics, Ghent,
Belgium), targeting the 16S)23S rDNA spacer
region, and Genotype Mycobacterium common
mycobacteria (CM) (Hain Lifescience, Nehren,
Germany), targeting the 23S rDNA region, have
been developed for this purpose. These tests are
based on reverse hybridisation of PCR amplicons
to membrane-bound probes covering the species-
speciﬁc variable regions of the target genes. The
assays are reported to be sensitive (100%) and
speciﬁc (94.4–100%) for identiﬁcation of most
common mycobacteria [2–5].
The GenoType Mycobacterium additional spe-
cies (AS) kit supplements the CM kit and allows
identiﬁcation of 16 additional mycobacterial spe-
cies (Mycobacterium asiaticum, Mycobacterium cela-
tum,Mycobacteriumgastri,Mycobacteriumgenavense,
Mycobacterium goodii, Mycobacterium haemophilum,
Mycobacterium heckeshornense, Mycobacterium kans-
asii, Mycobacterium lentiﬂavum, Mycobacterium
mucogenicum, Mycobacterium phlei, Mycobacterium
shimoidei, Mycobacterium simiae, Mycobacterium
smegmatis, Mycobacterium szulgai ⁄Mycobacterium
intermedium and Mycobacterium ulcerans). This test
has been available in Europe since 2004, but an
evaluation from a clinical laboratory has not been
published previously. The aim of the present study
was to assess the usefulness of the GenoType
Mycobacterium CM and AS tests for the routine
identiﬁcation of mycobacteria isolated from
patient specimens in Finland.
All new patient isolates (n = 219) sent to the
Finnish Mycobacterial Reference Laboratory dur-
ing October–December 2004 were included in the
study. The isolates were received either on solid
Lo¨wenstein–Jensen media, or in BACTEC-MGIT
(BD Biosciences, Franklin Lakes, NJ, USA) or
MB ⁄BacT (bioMe´rieux, Marcy l’Etoile, France)
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